In Figure 4, drug-targeted MR analyses revealed that a one-SD decrease in LDL-C predicted by variants at or near PCSK9 was associated with higher ORs of being diagnosed with IBD, UC, and CD with values of 1.75 (95%CI: 1.13-2.69, P = 0.011), 2.1 (95%CI: 1.28-3.42, P = 0.003), and 2.24 (95%CI: 1.11-4.5, P = 0.024), respectively. Here, PCSK9 is linked to inflammatory bowel disease.